(Q46534897)

22 December 2017

title

The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly (English)

1 reference

22 December 2017

author name string

Gilbert JA

1

1 reference

22 December 2017

Miell JP

2

1 reference

22 December 2017

Chambers SM

3

1 reference

22 December 2017

McGregor AM

4

1 reference

22 December 2017

Aylwin SJ

5

1 reference

22 December 2017

publication date

1 June 2005

1 reference

22 December 2017

published in

Clinical Endocrinology

1 reference

22 December 2017

volume

62

1 reference

22 December 2017

issue

6

1 reference

22 December 2017

page(s)

742-747

1 reference

22 December 2017

Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02278.X

Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02278.X

Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02278.X

Octreotide as primary therapy for acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02278.X

Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02278.X

Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02278.X

Guidelines for acromegaly management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02278.X

The treatment of de novo acromegalic patients with octreotide-LAR: efficacy, tolerability and cardiovascular effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02278.X

10.1111/J.1365-2265.2005.02278.X

21 January 2018

Identifiers

DOI

1 reference

22 December 2017

release_3jd55u7ejngajdb3dmxxsypo6m

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3jd55u7ejngajdb3dmxxsypo6m

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

22 December 2017